Pfizer and BioNTech Win FDA Approval for XFG COVID-19 Vaccine
NEW YORK, NY and MAINZ, Germany – August 27, 2026 Pfizer Inc. and BioNTech SE announced that the U.S....
Pfizer
Advertisement
Pfizer and Valneva Secure EMA Validation for Lyme Vaccine
NEW YORK and LYON, France, August 14, 2026 Pfizer Inc. and Valneva SE announced that the European Medicines Agency...
Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo
NEW YORK, July 30, 2026 Pfizer Inc. announced positive topline Phase 3 results for LITFULO™ (ritlecitinib) in patients with...
Pfizer’s PREVNAR 20 Selected for Québec Pediatric Program
KIRKLAND, Québec, Canada, July 29, 2026 Pfizer Canada ULC announced that PREVNAR 20™, its 20-valent pneumococcal conjugate vaccine, has...
Pfizer and BioNTech Win EU Approval for XFG COVID-19 Vaccine
NEW YORK and MAINZ, Germany, July 29, 2026 Pfizer Inc. and BioNTech SE announced that the European Commission (EC)...
Advertisements
Pfizer Inc. Wins FDA Priority Review for Prostate Cancer Therapy
NEW YORK, July 22, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
Chai Discovery Secures $400M to Transform AI Drug Discovery
SAN FRANCISCO, July 17, 2026 Chai Discovery has announced the successful completion of a $400 million Series C financing...
Pfizer Expands IBRANCE Label with New FDA Approval for HER2+ Breast Cancer
NEW YORK, June 24, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved IBRANCE®...
Pfizer Partners with Chai Discovery to Accelerate AI-Powered Drug Discovery
SAN FRANCISCO, June 4 2026 Chai Discovery has announced a strategic license agreement with Pfizer that will enable the...
Pfizer Reports Landmark Seven-Year LORBRENA Data in Advanced ALK-Positive Lung Cancer
NEW YORK | May 29, 2026 Pfizer announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial, demonstrating...
Advertisement
